Gastroparesis in Cystic Fibrosis
Primary Purpose
Gastroparesis
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
13^C Spirulina Platensis Gastric Emptying Breath Test (GEBT)
Sponsored by
About this trial
This is an interventional diagnostic trial for Gastroparesis focused on measuring Cystic Fibrosis, Pediatrics, Altered lung function
Eligibility Criteria
Inclusion Criteria:
- Patients age 4 years* and above with a genetically confirmed diagnosis of CF (*This age was chosen as patients younger than 4 years rarely undergo GES)
- Actively being followed at the University of Miami CF Center (i.e. seen within the past 5 years at a University of Miami pediatric or adult pulmonology clinic)
Exclusion Criteria:
- History of abdominal surgeries involving gastrointestinal luminal resection (i.e. small bowel or colonic resection that increases risk of post-operative strictures or narrowing of the lumen). Nissen fundoplication, gastrostomy tube placement, gynecologic surgeries, appendectomy, and/or cholecystectomy are not excluded.
- Gastrointestinal comorbidities that impact absorption such as Inflammatory Bowel Disease and Celiac Disease
- Known hypersensitivity to Spirulina, egg, milk or wheat allergens
- Patients not able to consume at least 50% of a standard test meal
- Pregnant women
- Adults unable to consent
- Prisoners
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Cystic Fibrosis
Healthy Normal
Arm Description
Patients who are diagnosed with Cystic Fibrosis.
Patients in this arm will be a sibling of patients who have been diagnosed with Cystic Fibrosis.
Outcomes
Primary Outcome Measures
Rate of gastric emptying
The kPCD value (13CO2 excretion rate) at any time t, is proportional to the rate of gastric emptying. Increasing kPCD values represent increasing rates of gastric emptying.
Secondary Outcome Measures
Rate of gastric emptying over time
The kPCD value (13CO2 excretion rate) at any time t, is proportional to the rate of gastric emptying. Increasing kPCD values represent increasing rates of gastric emptying.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05223881
Brief Title
Gastroparesis in Cystic Fibrosis
Official Title
13^C-Spirulina Platensis Gastric Emptying Breath Test for Diagnosis of Gastroparesis in Patients With Cystic Fibrosis
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Withdrawn
Why Stopped
Study is not feasible at this time due to staffing limitations
Study Start Date
February 14, 2022 (Anticipated)
Primary Completion Date
September 30, 2022 (Anticipated)
Study Completion Date
March 30, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Miami
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this research is to determine if an investigational device called the 13C-Spirulina Gastric Emptying Breath Test (GEBT), can accurately diagnose gastroparesis (delayed emptying of the stomach) in patients with Cystic Fibrosis (CF).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastroparesis
Keywords
Cystic Fibrosis, Pediatrics, Altered lung function
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Cystic Fibrosis
Arm Type
Experimental
Arm Description
Patients who are diagnosed with Cystic Fibrosis.
Arm Title
Healthy Normal
Arm Type
Active Comparator
Arm Description
Patients in this arm will be a sibling of patients who have been diagnosed with Cystic Fibrosis.
Intervention Type
Device
Intervention Name(s)
13^C Spirulina Platensis Gastric Emptying Breath Test (GEBT)
Intervention Description
After an overnight (minimum 8 hours) fast, patients are given a standardized test meal, after which they are administered the GEBT. Patients are asked to hold a glass tube in a comfortable position, take a deep breath and pause momentarily, blow gently into the tube for 5 - 10 seconds, slowly withdraw straw from tube while continuing to breath into tube, and immediately close the tube securely with the cap.
Primary Outcome Measure Information:
Title
Rate of gastric emptying
Description
The kPCD value (13CO2 excretion rate) at any time t, is proportional to the rate of gastric emptying. Increasing kPCD values represent increasing rates of gastric emptying.
Time Frame
4 hours
Secondary Outcome Measure Information:
Title
Rate of gastric emptying over time
Description
The kPCD value (13CO2 excretion rate) at any time t, is proportional to the rate of gastric emptying. Increasing kPCD values represent increasing rates of gastric emptying.
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
4 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patients age 4 years* and above with a genetically confirmed diagnosis of CF (*This age was chosen as patients younger than 4 years rarely undergo GES)
Actively being followed at the University of Miami CF Center (i.e. seen within the past 5 years at a University of Miami pediatric or adult pulmonology clinic)
Exclusion Criteria:
History of abdominal surgeries involving gastrointestinal luminal resection (i.e. small bowel or colonic resection that increases risk of post-operative strictures or narrowing of the lumen). Nissen fundoplication, gastrostomy tube placement, gynecologic surgeries, appendectomy, and/or cholecystectomy are not excluded.
Gastrointestinal comorbidities that impact absorption such as Inflammatory Bowel Disease and Celiac Disease
Known hypersensitivity to Spirulina, egg, milk or wheat allergens
Patients not able to consume at least 50% of a standard test meal
Pregnant women
Adults unable to consent
Prisoners
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daphna Katz, MD
Organizational Affiliation
University of Miami
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Gastroparesis in Cystic Fibrosis
We'll reach out to this number within 24 hrs